105 results on '"Kanzawa T"'
Search Results
2. Evaluation of hafnium nitride thin films sputtered from a hafnium nitride target
- Author
-
Kanzawa, T., Setojima, N., Miyata, Y., Gotoh, Y., Tsuji, H., and Ishikawa, J.
- Published
- 2008
- Full Text
- View/download PDF
3. Ionizing radiation induces apoptosis and inhibits neuronal differentiation in rat neural stem cells via the c-Jun NH2-terminal kinase (JNK) pathway
- Author
-
Kanzawa, T, Iwado, E, Aoki, H, Iwamaru, A, Hollingsworth, E F, Sawaya, R, Kondo, S, and Kondo, Y
- Published
- 2006
- Full Text
- View/download PDF
4. Melanotic cerebral astrocytoma: case report and literature review
- Author
-
Kanzawa, T., Takahashi, H., Hayano, Makoto, Mori, Shuichi, Shimbo, Yoshikatsu, and Kitazawa, Tomoji
- Published
- 1997
- Full Text
- View/download PDF
5. Targeting telomerase as therapies for malignant gliomas
- Author
-
Kondo, Y., Komata, T., Kanzawa, T., and Kondo, S.
- Published
- 2003
6. Tracking Control of an Aerial Blimp Robot Based on Image Information.
- Author
-
Fukao, T., Kanzawa, T., and Osuka, K.
- Published
- 2007
- Full Text
- View/download PDF
7. Inverse optimal tracking control of an aerial blimp robot.
- Author
-
Fukao, T., Kanzawa, T., and Osuka, K.
- Published
- 2005
- Full Text
- View/download PDF
8. A very fast FFT spectrum analyzer for radio astronomy.
- Author
-
Chikada, Y., Ishiguro, M., Hirabayashi, H., Morimoto, M., Morita, K., Kanzawa, T., Iwashita, H., Nakazima, K., Ishikawa, S., Takahashi, T., Handa, K., Kasuga, T., Okumura, S., Miyazawa, T., Nakazuru, T., Miura, K., and Nagasawa, S.
- Published
- 1986
- Full Text
- View/download PDF
9. EPR measurements of a two-dimensional spin frustrated system, BIPNNBNO with S = 1 and S= 1/2.
- Author
-
Kanzawa, T, Hosokoshi, Y, Katoh, K, Nishihara, S, Inoue, K, and Nojiri, H
- Published
- 2006
- Full Text
- View/download PDF
10. Ionizing radiation induces apoptosis and inhibits neuronal differentiation in rat neural stem cells via the c-Jun NH2-terminal kinase (JNK) pathway.
- Author
-
Kanzawa, T., Iwado, E., Aoki, H., Iwamaru, A., Hollingsworth, E. F., Sawaya, R., Kondo, S., and Kondo, Y.
- Subjects
- *
IONIZING radiation , *APOPTOSIS , *CELL death , *NEURAL stem cells , *LABORATORY rats , *DEVELOPMENTAL neurobiology - Abstract
A substantial number of neural stem cells (NSCs) continue to proliferate and generate neurons in the central nervous system throughout life. Ionizing radiation, an important adjuvant therapy for glioma patients, may damage NSCs and cause neuronal deficits, such as cognitive dysfunction and memory impairment. However, the precise mechanism of radiation effects on death and differentiation of NSCs remains largely unknown. Here, we found that radiation induced apoptosis in NSCs via the mitochondrial pathway, upregulating the ratio of Bax to Bcl-2 and releasing cytochrome c into the cytoplasm. Radiation also inhibited neuronal differentiation of NSCs by 50%. Of the three stress-associated mitogen-activated protein kinases (MAPKs), only c-Jun NH2-terminal kinase (JNK) was activated in NSCs after radiation. Interestingly, JNK inhibition by the specific inhibitor SP600125 rescued NSCs from apoptosis and improved neuronal differentiation. Furthermore, we examined whether radiation directly inhibits neuronal differentiation or not. Radiation did not affect the promoter activity of NeuroD, a basic helix–loop–helix transcription factor that regulates the expression of neuronal differentiation markers. Radiation induced more apoptosis in NeuroD-positive cells than NeuroD-negative cells. We concluded that radiation activates JNK and induces apoptosis, especially in neural progenitor cells, resulting in the inhibition of neurogenesis. Our findings raise the possibility that JNK inhibition has therapeutic potential in protecting NSCs from the adverse effects of radiation.Oncogene (2006) 25, 3638–3648. doi:10.1038/sj.onc.1209414; published online 20 February 2006 [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
11. Expression of transcription factor E2F1 and telomerase in glioblastomas: mechanistic linkage and prognostic significance.
- Author
-
Alonso MM, Fueyo J, Shay JW, Aldape KD, Jiang H, Lee O, Johnson DG, Xu J, Kondo Y, Kanzawa T, Kyo S, Bekele BN, Zhou X, Nigro J, McDonald JM, Yung WKA, and Gomez-Manzano C
- Published
- 2005
- Full Text
- View/download PDF
12. Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells.
- Author
-
Kanzawa, T., Germano, I.M., Komata, T., Ito, H., Kondo, Y., and Kondo, S.
- Subjects
- *
GLIOMAS , *CELLS , *PROTEINS , *APOPTOSIS , *LYSOSOMES , *ORGANELLES - Abstract
Autophagy is originally named as a process of protein recycling. It begins with sequestering cytoplasmic organelles in a membrane vacuole called autophagosome. Autophagosomes then fuse with lysosomes, where the materials inside are degraded and recycled. To date, however, little is known about the role of autophagy in cancer therapy. In this study, we present that temozolomide (TMZ), a new alkylating agent, inhibited the viability of malignant glioma cells in a dose-dependent manner and induced G2/M arrest. At a clinically achievable dose (100?µM), TMZ induced autophagy, but not apoptosis in malignant glioma cells. After the treatment with TMZ, microtubule-associated protein light-chain 3 (LC3), a mammalian homologue of Apg8p/Aut7p essential for amino-acid starvation-induced autophagy in yeast, was recruited on autophagosome membranes. When autophagy was prevented at an early stage by 3-methyladenine, a phosphatidylinositol 3-phosphate kinase inhibitor, not only the characteristic pattern of LC3 localization, but also the antitumor effect of TMZ was suppressed. On the other hand, bafilomycin A1, a specific inhibitor of vacuolar type H+-ATPase, that prevents autophagy at a late stage by inhibiting fusion between autophagosomes and lysosomes, sensitized tumor cells to TMZ by inducing apoptosis through activation of caspase-3 with mitochondrial and lysosomal membrane permeabilization, while LC3 localization pattern stayed the same. These results indicate that TMZ induces autophagy in malignant glioma cells. Application of an autophagy inhibitor that works after the association of LC3 with autophagosome membrane, such as bafilomycin A1, is expected to enhance the cytotoxicity of TMZ for malignant gliomas.Cell Death and Differentiation (2004) 11, 448-457. doi:10.1038/sj.cdd.4401359 Published online 9 January 2004 [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
13. Inhibition of platelet-derived growth factor signalling induces autophagy in malignant glioma cells.
- Author
-
Takeuchi, H, Kanzawa, T, Kondo, Y, and Kondo, S
- Subjects
- *
BRAIN cancer , *GLIOMA treatment , *MICROSURGERY , *RADIOTHERAPY , *DRUG therapy , *CANCER treatment - Abstract
Malignant gliomas highly coexpress platelet-derived growth factor (PDGF) and its receptor, suggesting the presence of an autocrine loop. Therefore, disruption of PDGF ligand/receptor complex represents a promising strategy for the treatment of malignant gliomas. However, the mechanisms of the antitumour effect exerted by the inhibition of PDGF-mediated cell growth remain unclear. In the present study, using anti-PDGF neutralising antibody, we investigated the effect of the inhibition of PDGF signalling on malignant glioma U87-MG, D54, and T98G cells with high levels of PDGF-A and -B. As a control, normal fibroblast MRC5 cells expressing low levels of PDGF-A and -B were used. Treatment with anti-PDGF neutralising antibody did not affect the expressions of PDGF-A, PDGF-B, and Akt, but suppressed the level of phosphorylated Akt in tumour cells, indicating the inhibition of PDGF signalling. The cell viability of all malignant glioma cells tested in this study was significantly inhibited in a time-dependent manner following the treatment compared to that of fibroblast cells (P<0.02 to <0.05). The antitumour effect of anti-PDGF antibody was suppressed by the activation of Akt and enhanced by the downregulation of Akt. Interestingly, the inhibition of PDGF signalling induced the development of acidic vesicular organelles and the autophagosome membrane association of the microtubule-associated protein light chain 3, which are characteristic of autophagy, in malignant glioma cells, while apoptotic cell death was not observed. Together these findings imply a new concept of autophagy for PDGF autocrine inhibition in malignant gliomas.British Journal of Cancer (2004) 90, 1069-1075. doi:10.1038/sj.bjc.6601605 www.bjcancer.com [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
14. Inhibition of telomerase activity in malignant glioma cells correlates with their sensitivity to temozolomide.
- Author
-
Kanzawa, T., Germano, I.M., Kondo, Y., Ito, H., Kyo, S., and Kondo, S.
- Subjects
- *
ANTINEOPLASTIC agents , *GLIOMAS , *TELOMERASE , *REVERSE transcriptase , *RNA analysis , *BIOCHEMISTRY , *CELL death , *CELL division , *COMPARATIVE studies , *DRUG resistance in cancer cells , *DOSE-effect relationship in pharmacology , *ENZYME inhibitors , *GENE expression , *GENES , *PHENOMENOLOGY , *RESEARCH methodology , *MEDICAL cooperation , *GENETIC mutation , *POLYMERASE chain reaction , *PURINES , *RESEARCH , *RNA , *TRANSCRIPTION factors , *TRANSFERASES , *DNA-binding proteins , *EVALUATION research , *REVERSE transcriptase polymerase chain reaction , *CANCER cell culture , *DACARBAZINE , *PHARMACODYNAMICS - Abstract
Temozolomide (TMZ, 3,4-dihydro-3-methyl-4-oxoimidazo [5,1-d]-as-tetrazine-8-carboxamide) is a new alkylating agent with promising antitumour efficacy for malignant gliomas. The resistance of tumour cells to TMZ is primarily associated with levels of the alkylguanine alkyltransferase (AGT). O(6)-benzylguanine (O(6)-BG), an inhibitor for AGT, reduced resistance to TMZ. Recently, it has been demonstrated that chemosensitivity of tumour cells is related to a decline in telomerase activity. However, it is unknown if TMZ sensitivity of malignant glioma cells correlates with telomerase. In this study, using malignant glioma cells with low levels of AGT (U373-MG and U87-MG) and high levels of AGT (T98G), we investigated the association among AGT, telomerase, and TMZ sensitivity. U373-MG and U87-MG cells were sensitive to TMZ (IC(50) for a 2-day treatment=100 microM), while T98G cells were resistant to TMZ (IC(50) for a 2-day treatment >500 microM). Treatment with TMZ (100 microM) suppressed telomerase activity in U373-MG and U87-MG cells in a time-dependent manner, but not in T98G cells. The downregulation of telomerase activity in U373-MG and U87-MG cells was due to inhibition of the human telomerase reverse-transcriptase (hTERT) gene expression at the transcriptional level. This inhibitory effect was induced by interfering with transcription factor Sp1 binding sites of the hTERT core promoter. Interestingly, O(6)-BG not only sensitised T98G cells to TMZ, but also suppressed telomerase activity. These findings suggest that response of malignant glioma cells to TMZ can be monitored by reduction in telomerase activity. Therefore, quantification of telomerase activity during or after treatment with TMZ may be a useful marker to detect treatment efficacy. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
15. Antitumour effect of cyclin-dependent kinase inhibitors (p16(INK4A), p18(INK4C), p19(INK4D), p21(WAF1/CIP1) and p27(KIP1)) on malignant glioma cells.
- Author
-
Komata, T., Kanzawa, T., Takeuchi, H., Germano, I.M., Schreiber, M., Kondo, Y., and Kondo, S.
- Subjects
- *
ANTINEOPLASTIC agents , *ENZYME inhibitors , *GLIOMAS , *CELL lines , *COMPARATIVE studies , *RESEARCH methodology , *MEDICAL cooperation , *PROTEINS , *RESEARCH , *TRANSFERASES , *EVALUATION research , *CELL cycle proteins , *CHEMICAL inhibitors - Abstract
Cyclin-dependent kinase inhibitors (CDKIs) are considered as novel anticancer agents because of their ability to induce growth arrest or apoptosis in tumour cells. It has not yet been fully determined, however, which CDKI is the best candidate for the treatment of malignant gliomas and whether normal brain tissues are affected by CDKI expression. Using recombinant adenoviral vectors that express CDKIs (p16(INK4A), p18(INK4C), p19(INK4D), p21(WAF1/CIP1) and p27(KIP1)), we compared the antitumour effect of CDKIs on malignant glioma cell lines (A172, GB-1, T98G, U87-MG, U251-MG and U373-MG). p27(KIP1) showed higher ability to suppress the growth of all tumour cells tested than other CDKIs. Interestingly, overexpression of p27(KIP1) induced autophagic cell death, but not apoptosis in tumour cells. On the other hand, p27(KIP1) overexpression did not inhibit the viability of cultured astrocytes (RNB) nor induced autophagy. Overall, our findings suggest that gene transfer of p27(KIP1) may be a promising approach for the therapy of malignant gliomas. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
16. Current and future gene therapy for malignant gliomas.
- Author
-
Kanzawa T, Ito H, Kondo Y, and Kondo S
- Published
- 2003
17. Development of superconducting magnet with low electric power loss for SMES.
- Author
-
Hayakawa, K., Nakano, T., Minami, M., Fujiwara, M., Kanzawa, T., Terai, S., Haraguchi, E., Ryouman, A., and Murakami, Y.
- Published
- 1993
- Full Text
- View/download PDF
18. A 6 × 320-MHz 1024-channel FFT cross-spectrum analyzer for radio astronomy.
- Author
-
Chikada, Y., Ishiguro, M., Hirabayashi, H., Morimoto, M., Morita, K., Kanzawa, T., Iwashita, H., Nakazima, K., Ishikawa, S., Takahashi, T., Handa, K., Kasuga, T., Okumura, S., Miyazawa, T., Nakazuru, T., Miura, K., and Nagasawa, S.
- Published
- 1987
- Full Text
- View/download PDF
19. Fabrication and field emission properties of gated field emitter arrays with hafnium nitride cathode.
- Author
-
Gotoh, Y., Setojima, N., Miyata, Y., Kanzawa, T., Tsuji, H., and Ishikawa, J.
- Published
- 2007
- Full Text
- View/download PDF
20. High-frequency ESR study on a frustrated mixed spin system BIPNNBNO.
- Author
-
Kanzawa, T., Hosokoshi1, Y., Katoh, K., Inoue, K., and Nojiri, H.
- Published
- 2011
- Full Text
- View/download PDF
21. Robust control of coupled bending and torsional vibrations and contact force of a constrained flexible arm.
- Author
-
Matsuno, F. and Kanzawa, T.
- Published
- 1996
- Full Text
- View/download PDF
22. Delayed peak antibody titers after the second dose of SARS-CoV-2 vaccine in solid organ transplant recipients: Prospective cohort study.
- Author
-
Unagami K, Yoshikawa M, Egawa H, Ohfuji S, Natori Y, Oki R, Mori T, Hattori H, Ishiwatari A, Kanzawa T, Shimizu T, Omoto K, Inui M, Masano Y, Ito T, Nakajima D, Babazono T, Takagi T, Nunoda S, Tomimaru Y, Imamura R, Miyagawa S, Toda K, Hatano E, Date H, Kyakuno M, Takahara S, Yuzawa K, Tanimine N, Ohdan H, Ishida H, and Hirota Y
- Subjects
- Humans, Prospective Studies, Male, Female, Middle Aged, Aged, Adult, 2019-nCoV Vaccine mRNA-1273 immunology, 2019-nCoV Vaccine mRNA-1273 administration & dosage, Immunoglobulin G blood, Vaccination, Antibodies, Viral blood, COVID-19 prevention & control, COVID-19 immunology, Organ Transplantation, Transplant Recipients, SARS-CoV-2 immunology, BNT162 Vaccine immunology, BNT162 Vaccine administration & dosage, COVID-19 Vaccines immunology, COVID-19 Vaccines administration & dosage
- Abstract
Poor post-vaccination production of antibody against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a concern among solid organ transplant (SOT) recipients. Furthermore, the timing and kinetics of antibody titers after the second vaccine dose are unknown. We conducted a multicenter prospective observational study that included 614 SOT recipients: 460 kidney, 53 heart, 50 liver, 20 lung, and 31 simultaneous pancreas-kidney (SPK). The participants received two doses of the mRNA vaccine (Pfizer BNT162b2 or Moderna mRNA-1273), as indicated. Serum samples were collected before the first and second vaccinations and at 1, 3, and 6 months after the second vaccine dose, which were then assessed for SARS-CoV-2 antibodies. The overall seropositivity rate was 43% at 1 month after administration of the second vaccine dose; it gradually increased to 68% at 3 months after second dose administration and to 70% at 6 months. In addition, recipient of kidney, lung or SPK transplants had lower antibody titers at the 3- and 6-month time points than did the other recipients. SOT recipients acquired SARS-CoV-2 S-IgG antibodies slowly, and the peak titer differed significantly from that of the general population., Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Yoshio Hirota reports financial support was provided by Health Labor Administration. Yoshio Hirota reports a relationship with Japan Health Labor Administration that includes: funding grants. The authors of this manuscript have no conflicts of interest to disclose as described by the Vaccine. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier Ltd. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
23. The medical cost and outcome of desensitization protocol in kidney transplantation recipients with high immunological risks.
- Author
-
Maenosono R, Unagami K, Oki R, Fujiwara Y, Banno T, Okada D, Yagisawa T, Kanzawa T, Hirai T, Omoto K, Hanafusa N, Azuma H, Takagi T, and Ishida H
- Subjects
- Humans, Transplant Recipients, Treatment Outcome, Graft Rejection prevention & control, Graft Survival, Rituximab adverse effects, Kidney Transplantation adverse effects
- Abstract
Background: Kidney transplantation is a well-established alternative in renal replacement therapy. Compared with hemodialysis, low-immunological-risk kidney transplantation can reduce the medical treatment costs associated with end-stage renal disease. However, there are few reports on whether high-immunological-risk kidney transplantation reduces the financial burden on governments. We investigated the medical costs of high-immunological-risk kidney transplantation in comparison with the cost of hemodialysis in Japan., Methods: We compared the medical costs of high-immunological-risk kidney transplantation with those of hemodialysis. 15 patients who underwent crossmatch-positive and/or donor-specific antibody-positive kidney transplantations between 2020 and 2021 were enrolled in this study. The patients received intravenous immunoglobulin, plasmapheresis, and rituximab as desensitizing therapy., Results: Acute antibody-mediated rejection was detected in nine (60%) recipients, while there were no indications of graft function deterioration during the follow-up. For each patient, the transplant hospitalization cost was 38 428 ± 8789 USD. However, the cumulative costs were 59 758 ± 10 006 USD and 79 781 ± 16 366 USD, at 12 and 24 months, respectively. Compared with hemodialysis (34 286 USD per year), high-immunological-risk kidney transplantation tends to be expensive in the first year, but the cost is likely to be lower than that of hemodialysis after 3 years., Conclusions: Although kidney transplantation is initially expensive compared with hemodialysis, the medical cost becomes advantageous after 3 years even in kidney transplant recipients with high immunological risk., (© 2024 The Japanese Urological Association.)
- Published
- 2024
- Full Text
- View/download PDF
24. High brain natriuretic peptide level is associated with severe stroke in patients taking oral anticoagulants: A sub-analysis of the PASTA registry study.
- Author
-
Suda S, Iguchi Y, Yagita Y, Kanzawa T, Okubo S, Fujimoto S, Kono Y, and Kimura K
- Subjects
- Female, Humans, Aged, 80 and over, Aged, Natriuretic Peptide, Brain, Biomarkers, Ischemic Stroke, Stroke complications, Atrial Fibrillation complications, Atrial Fibrillation drug therapy, Atrial Fibrillation diagnosis
- Abstract
Background: Brain natriuretic peptides (BNP) are an important diagnostic and prognostic marker in patients with heart failure. However, the relationship between BNP levels and stroke severity in patients with atrial fibrillation (AF) remains unelucidated. In this study, we aimed to investigate the association between stroke severity at admission and BNP levels., Methods: In this prospective observational study, we used data from 513 patients with AF and acute ischemic stroke treated with oral anticoagulants (OAC) registered in the Multicenter Prospective Analysis of Stroke Patients Taking Oral Anticoagulants study. The patients were divided into two groups: high-BNP (≥200 pg/mL) and low-BNP level (<200 pg/mL) groups. We compared the clinical characteristics between the two groups and determined the effect of BNP levels on stroke severity on admission., Results: Among the 513 enrolled patients, 248 (females, n = 30; median age, 82 years) and 265 (females, n = 76; median age, 71 years) were assigned to the high- and low-BNP level groups, respectively. The high-BNP level group had a higher proportion of patients with severe stroke (National Institutes of Health Stroke Scale score, ≥10) on admission (49.2% vs. 32.8%, p = 0.002) and major vessel occlusion (57.5% vs. 39.2%, p < 0.0001) than that had by the low-BNP level group. Multivariate analysis showed that high BNP level was independently associated with severe stroke on admission (odds ratio 1.07, 95% confidence interval 1.00-1.15; p = 0.0478)., Conclusions: High BNP level compared with low BNP level was associated with severe stroke and major vessel occlusion, even before OAC treatment., Competing Interests: Declaration of competing interest S.S. received research funding from the All Japan Coffee Association and lecture fees from Daiichi Sankyo Co. Ltd. and Eisai Co., Ltd. Y.I. received lecture fees from Bayer Healthcare Co. Ltd., Pfizer Japan Inc., Nippon Boehringer Ingelheim Co. Ltd., Takeda Pharmaceutical Co. Ltd., Otsuka Pharmaceutical Co., Ltd., and Daiichi Sankyo Co. Ltd. Research funding was obtained from Sanofi Co., Ltd. Y.Y. received lecture fees from Daiichi Sankyo Co. Ltd. T.K. received lecture fees from Bayer Healthcare Co. Ltd., Nippon Boehringer Ingelheim Co. Ltd., and Daiichi Sankyo Co. Ltd. S.F. received personal lecture fees (not related to the current work) from Takeda Pharmaceutical Co. Ltd., Nippon Boehringer Ingelheim, Co. Ltd., Otsuka Pharmaceutical, Co. Ltd., Bayer Yakuhin, Ltd., Pfizer Japan Inc., Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., and Bristol-Myers Squibb Co. Ltd. K.K. received lecture fees from Bristol-Myers Squibb Co. Ltd., Nippon Boehringer Ingelheim Co. Ltd., Bayer Healthcare Co. Ltd., and Daiichi Sankyo Co. Ltd. Research funding from Nippon Boehringer Ingelheim Co. Ltd. And Daiichi Sankyo Co. Ltd., (Copyright © 2024 Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
25. Higher Donor Age and Severe Microvascular Inflammation Are Risk Factors for Chronic Rejection After Treatment of Active Antibody-Mediated Rejection.
- Author
-
Banno T, Hirai T, Oki R, Yagisawa T, Unagami K, Kanzawa T, Omoto K, Shimizu T, Ishida H, and Takagi T
- Subjects
- Humans, Middle Aged, Kidney, Risk Factors, Inflammation etiology, Graft Rejection, Graft Survival, HLA Antigens, Antibodies, Kidney Transplantation adverse effects, Kidney Transplantation methods
- Abstract
Recent developments in intensive desensitization protocols have enabled kidney transplantation in human leukocyte antigen (HLA)-sensitized recipients. However, cases of active antibody-mediated rejection (AABMR), when they occur, are difficult to manage, graft failure being the worst-case scenario. We aimed to assess the impact of our desensitization and AABMR treatment regimen and identify risk factors for disease progression. Among 849 patients who underwent living-donor kidney transplantation between 2014 and 2021 at our institution, 59 were diagnosed with AABMR within 1 year after transplantation. All patients received combination therapy consisting of steroid pulse therapy, intravenous immunoglobulin, rituximab, and plasmapheresis. Multivariable analysis revealed unrelated donors and preformed donor-specific antibodies as independent risk factors for AABMR. Five-year death-censored graft survival rate was not significantly different between patients with and without AABMR although 27 of 59 patients with AABMR developed chronic AABMR (CABMR) during the study period. Multivariate Cox proportional hazard regression analysis revealed that a donor age greater than 59 years and microvascular inflammation (MVI) score (g + ptc) ≥4 at AABMR diagnosis were independent risk factors for CABMR. Our combination therapy ameliorated AABMR; however, further treatment options should be considered to prevent CABMR, especially in patients with old donors and severe MVI., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2024 Banno, Hirai, Oki, Yagisawa, Unagami, Kanzawa, Omoto, Shimizu, Ishida and Takagi.)
- Published
- 2024
- Full Text
- View/download PDF
26. High pre-stroke CHADS 2 score predicts unfavorable functional outcome in acute cardioembolic stroke patients prescribed oral anticoagulant therapy: A sub-analysis of the PASTA registry study.
- Author
-
Sakai K, Suda S, Iguchi Y, Abe A, Yagita Y, Kanzawa T, Okubo S, Fujimoto S, and Kimura K
- Subjects
- Humans, Male, Risk Factors, Retrospective Studies, Anticoagulants adverse effects, Registries, Embolic Stroke complications, Stroke diagnosis, Stroke drug therapy, Stroke etiology, Atrial Fibrillation complications, Atrial Fibrillation diagnosis, Atrial Fibrillation drug therapy
- Abstract
Background and Purpose: The impact of CHADS
2 score on outcome in patients with stroke taking an oral anticoagulant (OAC) has not yet been fully elucidated. We investigated the association between pre-stroke CHADS2 score and outcome at discharge in patients with acute cardioembolic (CE) stroke due to atrial fibrillation (AF) who were prescribed OAC., Methods: The data of 548 OAC-treated patients with AF and CE stroke who were registered in the multicenter Prospective Analysis of Stroke patients Taking oral Anticoagulants (PASTA) study were analyzed. High CHADS2 score was defined as a pre-stroke CHADS2 score ≥2. Unfavorable outcome was defined as a modified Rankin scale (mRS) of 3-6. The impacts of pre-stroke CHADS2 score on outcome at discharge were evaluated using multiple logistic regression analysis., Result: A high CHADS2 score was found in 472/548 patients and unfavorable outcome was found in 330/548 patients. In patients with unfavorable outcome, age, male sex, pre-stroke CHADS2 score, initial National Institute Health Stroke Scale (NIHSS) score, and glucose level on admission were significantly higher, whereas creatinine clearance and body weight were significantly lower, than those with favorable outcome (each p < 0.001). Multivariate logistic regression analysis indicated that high CHADS2 score (OR 2.18, 95 %CI 1.08-4.42, p = 0.031), pre-stroke mRS (OR 2.21, 95 %CI 1.69-2.67, p < 0.001), and initial NIHSS score (OR 1.19, 95 %CI 1.17-1.24, p < 0.001) were independently associated with unfavorable outcome., Conclusion: Pre-stroke CHADS2 score was associated with poor outcome in patients with cardioembolic stroke due to AF, even in those taking OAC., Competing Interests: Declaration of Competing Interest S.S received research funding from Pfizer Co., Ltd and lecture fees from Daiichi Sankyo Co. Ltd, Eisai Co., Ltd, and Bristol-Myers Squibb Co. Ltd. Y.I. received lecture fees from Bayer Healthcare Co. Ltd.; Pfizer Japan Inc.; Nippon Boehringer Ingelheim Co. Ltd.; Takeda Pharmaceutical Co. Ltd.; Otsuka Pharmaceutical Co., Ltd.; and Daiichi Sankyo Co. Ltd. Research funding was obtained from Sanofi Co., Ltd. Y.Y. received lecture fees from Daiichi Sankyo Co. Ltd. T.K. received lecture fees from Bayer Healthcare Co. Ltd.; Nippon Boehringer Ingelheim Co. Ltd.; and Daiichi Sankyo Co. Ltd. S.F. received personal lecture fees (not related to the current work) from Takeda Pharmaceutical Co. Ltd.; Nippon Boehringer Ingelheim, Co. Ltd.; Otsuka Pharmaceutical, Co. Ltd.; Bayer Healthcare Co. Ltd.; Pfizer Japan Inc.; Daiichi Sankyo Co. Ltd.; Eisai Co. Ltd.; and Bristol-Myers Squibb Co. Ltd. K.K. received lecture fees from Bristol-Myers Squibb Co. Ltd.; Nippon Boehringer Ingelheim Co. Ltd.; Bayer Healthcare Co. Ltd.; and Daiichi Sankyo Co. Ltd. Research funding was received from Nippon Boehringer Ingelheim Co. Ltd. and Daiichi Sankyo Co. Ltd., (Copyright © 2023 Elsevier Inc. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
27. En bloc kidney transplantation from pediatric donors to teenage recipients: Two case reports.
- Author
-
Yagisawa T, Kanzawa T, Hirai T, Unagami K, Shirai Y, Ishizuka K, Miura K, Hattori M, Ishida H, and Takagi T
- Abstract
Introduction: Since the implementation of the new selection criteria in 2018, kidney donations from pediatric patients have been prioritized for pediatric recipients and kidney donations from pediatric donors have increased in Japan. Herein, we present two cases of en bloc kidney transplantation., Case Presentation: Case 1: A 19-year-old male patient who had been on hemodialysis for 5 years due to end-stage renal disease. After brain death, a graft from a 5-year-old boy was transplanted into the right iliac fossa. Case 2: A 19-year-old male patient, who had previously undergone a living kidney transplantation at the age of 3, received a secondary cadaveric kidney transplantation in the left iliac fossa. The graft was procured from a 17-month-old girl following cardiac death., Conclusion: This report will help surgeons perform en bloc kidney transplantation in the growing number of pediatric kidney donations, such as those in Japan., Competing Interests: None declared., (© 2023 The Authors. IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of Japanese Urological Association.)
- Published
- 2023
- Full Text
- View/download PDF
28. Resumption of oral anticoagulation in patients with non-valvular atrial fibrillation after intracerebral hemorrhage: A sub-analysis of the PASTA registry study.
- Author
-
Suda S, Iguchi Y, Yagita Y, Kanzawa T, Okubo S, Fujimoto S, Kono Y, and Kimura K
- Abstract
Purpose: To investigate the rate and timing of oral anticoagulant (OAC) resumption and its safety in patients after intracerebral hemorrhage (ICH) in current clinical practice in Japan., Methods: We conducted a sub-analysis of the PASTA registry, an observational, multicenter registry of 1043 patients with stroke receiving OACs in Japan, by including patients with ICH on OAC treatment for non-valvular atrial fibrillation (NVAF). The clinical characteristics of the patients in the resumption and non-resumption groups, rate and timing of OAC resumption, its safety, and switching of OACs after ICH were investigated., Results: Of the 160 patients (women, n = 52; median age, 77 years) included, OACs were resumed in 108 (68%) at a median of 7 days (interquartile range, 4-11) after acute ICH onset. The non-resumption group had higher rates of hematoma expansion (21.2% vs. 7.4%; P = 0.0118) and modified Rankin Scale (mRS) scores at discharge (4 (Suda et al., 2019; Steiner et al., 2014 [3, 4]) vs. 4 (Suda et al., 2019; Steiner et al., 2014; Pasquini et al., 2014 [3-5]); P = 0.0302}. The resumption rate in the mRS 0-4 group was higher than that in the mRS 5 group (75.2% vs. 46.5%; P = 0.00006). The number of days to resumption after ICH onset was longer in the mRS 5 than that in the mRS 0-4 group (median 12 days vs. 7 days, P = 0.0065). There were no significant differences in new-onset ICH, symptomatic hematoma expansion, or gastrointestinal bleeding between groups (P > 0.05)., Conclusions: Early resumption of OAC for NVAF in patients after ICH appeared to be safe. Expected functional outcomes at discharge were associated with OAC resumption and with the timing of resumption., Registration: https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000034958., Competing Interests: Declaration of Competing Interest S·S received research funding from the All Japan Coffee Association and Pfizer Co., Ltd. and lecture fees from Daiichi Sankyo Co. Ltd., Eisai Co., Ltd. and, and Bristol-Myers Squibb Co. Ltd. Y.I. received lecture fees from Bayer Healthcare Co. Ltd.; Pfizer Japan Inc.; Nippon Boehringer Ingelheim Co. Ltd.; Takeda Pharmaceutical Co. Ltd.; Otsuka Pharmaceutical Co., Ltd.; and Daiichi Sankyo Co. Ltd. Research funding was obtained from Sanofi Co., Ltd. T.K. received lecture fees from Bayer Healthcare Co. Ltd.; Nippon Boehringer Ingelheim Co. Ltd.; and Daiichi Sankyo Co. Ltd. S.F. received personal lecture fees (not related to the current work) from Takeda Pharmaceutical Co. Ltd.; Nippon Boehringer Ingelheim, Co. Ltd.; Otsuka Pharmaceutical, Co. Ltd.; Bayer Healthcare Co. Ltd.; Pfizer Japan Inc.; Daiichi Sankyo Co. Ltd.; Eisai Co. Ltd.; and Bristol-Myers Squibb Co. Ltd. Y.K. received research funding from Sanofi Co. Ltd. K.K. received lecture fees from Bristol-Myers Squibb Co. Ltd.; Nippon Boehringer Ingelheim Co. Ltd.; Bayer Healthcare Co. Ltd.; and Daiichi Sankyo Co. Ltd. Research funding from Nippon Boehringer Ingelheim Co. Ltd. and Daiichi Sankyo Co. Ltd., (Copyright © 2023 Elsevier B.V. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
29. Association between Living Conditions and the Risk Factors, Etiology, and Outcome of Ischemic Stroke in Young Adults.
- Author
-
Kono Y, Terasawa Y, Sakai K, Iguchi Y, Nishiyama Y, Nito C, Suda S, Kimura K, Murakami Y, Kanzawa T, Yamashiro K, Tanaka R, and Okubo S
- Subjects
- Male, Humans, Young Adult, Adult, Middle Aged, Social Conditions, Risk Factors, Smoking adverse effects, Smoking epidemiology, Ischemic Stroke, Stroke epidemiology, Stroke etiology
- Abstract
Objective In recent decades, living conditions have changed drastically. However, there are few data regarding the interaction between living conditions and the risk of ischemic stroke (IS) in young adults. The present study explored the association between living conditions or marital status and the risk factors, etiology, and outcome of IS in young adults. Methods We prospectively enrolled patients with incident IS who were 20-49 years old from 37 clinical stroke centers. We collected the demographic data, living conditions, marital status, vascular risk factors, disease etiology, treatment, and outcomes at discharge. A comparison group was established using the official statistics of Japan. We categorized patients into the two groups based on living conditions: solitary group and cohabiting group. Clinical characteristics were then compared between living conditions. Results In total, 303 patients were enrolled (224 men; median age at the onset: 44 years old). Significant factors associated with the incidence of IS were as follows: solitary status, body mass index >30 kg/m
2 , current smoking, heavy alcohol consumption, hypertension, diabetes mellitus, and dyslipidemia. Furthermore, in the solitary group, the proportions of men, unmarried individuals, and current smokers were significantly higher than in the cohabiting group. In addition, poor outcomes (modified Rankin Scale ≥4) of IS were more common in the solitary group than in the cohabiting group. Conclusion Our study showed that not only conventional vascular risk factors but also living conditions, especially living alone while unmarried, were independent risk factors for IS in young adults.- Published
- 2023
- Full Text
- View/download PDF
30. Safety of recanalization therapy in patients with acute ischemic stroke on direct oral anticoagulants: A sub-analysis of PASTA registry study.
- Author
-
Suda S, Abe A, Iguchi Y, Yagita Y, Kanzawa T, Okubo S, Fujimoto S, Kono Y, and Kimura K
- Subjects
- Humans, Female, Aged, 80 and over, Tissue Plasminogen Activator adverse effects, Prospective Studies, Treatment Outcome, Registries, Anticoagulants therapeutic use, Ischemic Stroke drug therapy, Stroke drug therapy, Stroke complications, Brain Ischemia drug therapy, Brain Ischemia complications
- Abstract
Background: The safety of intravenous recombinant tissue plasminogen activator (rtPA) and mechanical thrombectomy (MT) in patients treated with direct oral anticoagulants (DOACs) before stroke has not been fully investigated. Therefore, we aimed to investigate the safety of recanalization therapy in patients receiving DOACs., Methods: We assessed data from a prospective multicenter registry of patients with stroke, including those with acute ischemic stroke (AIS) treated with rtPA and/or MT who were administered DOACs. We evaluated the safety of recanalization considering the DOACs dosage and interval between the last DOAC intake and recanalization., Results: The final analysis included 108 patients (women, n = 54; median age, 81 years; DOAC overdose, n = 7; appropriate dose, n = 74; and inappropriate low dose, n = 27). The rate of any ICH differed significantly among overdose-, appropriate dose-, and inappropriate-low dose DOACs groups (71.4, 23.0, and 33.3%, respectively; P = 0.0121), whereas no significant difference was observed in respect of symptomatic ICH (P = 0.6895). Multivariate analysis showed that the National Institutes of Health Stroke Scale score on admission (odds ratio [OR]: 1.06, 95% confidence interval [CI]: 1.01-1.11; P = 0.0267) and overdose-DOAC (OR: 8.40, 95% CI: 1.24-56.88; P = 0.0291) were independently associated with any ICH. No relationship was observed between the timing of the last DOAC intake and occurrence of ICH in patients treated with rtPA and/or MT (all P > 0.05)., Conclusion: Recanalization therapy during DOAC treatment may be safe in selected patients with AIS, if it is performed >4 h after the last DOAC intake and the patient is not overdosed with DOACs., Registration: https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000034958., Competing Interests: Declaration of Competing Interest S·S received research funding from the All Japan Coffee Association and Pfizer Co., Ltd. and lecture fees from Daiichi Sankyo Co. Ltd. and Eisai Co., Ltd. Y.I. received lecture fees from Bayer Healthcare Co. Ltd.; Pfizer Japan Inc.; Nippon Boehringer Ingelheim Co. Ltd.; Takeda Pharmaceutical Co. Ltd.; Otsuka Pharmaceutical Co., Ltd.; and Daiichi Sankyo Co. Ltd. Research funding was obtained from Sanofi Co., Ltd. T.K. received lecture fees from Bayer Healthcare Co. Ltd.; Nippon Boehringer Ingelheim Co. Ltd.; and Daiichi Sankyo Co. Ltd. S.F. received personal lecture fees (not related to the current work) from Takeda Pharmaceutical Co. Ltd.; Nippon Boehringer Ingelheim, Co. Ltd.; Otsuka Pharmaceutical, Co. Ltd.; Bayer Healthcare Co. Ltd.; Pfizer Japan Inc.; Daiichi Sankyo Co. Ltd.; Eisai Co. Ltd.; and Bristol-Myers Squibb Co. Ltd. Y.K. received research funding from Sanofi Co. Ltd. K.K. received lecture fees from Bristol-Myers Squibb Co. Ltd.; Nippon Boehringer Ingelheim Co. Ltd.; Bayer Healthcare Co. Ltd.; and Daiichi Sankyo Co. Ltd. Research funding from Nippon Boehringer Ingelheim Co. Ltd. and Daiichi Sankyo Co. Ltd., (Copyright © 2023 Elsevier B.V. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
31. Vitamin K antagonists but not non-vitamin K antagonists in addition on antiplatelet therapy should be associated with increase of hematoma volume and mortality in patients with intracerebral hemorrhage: A sub-analysis of PASTA registry study.
- Author
-
Nomura K, Suda S, Abe A, Iguchi Y, Yagita Y, Kanzawa T, Okubo S, Fujimoto S, and Kimura K
- Subjects
- Humans, Anticoagulants adverse effects, Platelet Aggregation Inhibitors therapeutic use, Administration, Oral, Cerebral Hemorrhage diagnostic imaging, Cerebral Hemorrhage drug therapy, Cerebral Hemorrhage chemically induced, Hematoma diagnostic imaging, Hematoma drug therapy, Intracranial Hemorrhages chemically induced, Registries, Fibrinolytic Agents therapeutic use, Stroke diagnostic imaging, Stroke drug therapy, Atrial Fibrillation drug therapy
- Abstract
Background and Purpose: Prior concomitant use of vitamin K antagonists (VKAs) and antiplatelet (AP) therapy increase the hematoma volume and mortality compared with VKA monotherapy in patients with intracranial hemorrhage (ICH). However, the prior concomitant use of non-vitamin K oral antagonists (NOACs) and AP has not been clarified., Methods: We conducted a PASTA registry study, which was an observational, multicenter, registry of 1043 patients with stroke receiving oral anticoagulants (OACs) in Japan. In the present study, ICH from the PASTA registry was used to analyze the clinical characteristics including mortality among the four groups (NOAC, VKA, NOAC and AP, and VKA and AP) using univariate and multivariate analyses., Results: Among the 216 patients with ICH, 118 (54.6%), 27 (12.5%), 55 (25.5%), 16 (7.4%) were taking NOAC monotherapy, NOAC and AP, VKA, and VKA and AP, respectively. In-hospital mortality rates were the highest in VKA and AP (31.3%) than in NOACs (11.9%), NOACs and AP (7.4%), and VKA (7.3%). Multivariate logistic regression analysis demonstrated that the concomitant use of VKA and AP (odds ratio [OR], 20.57; 95% confidence interval [CI], 1.75-241.75, p = 0.0162), initial National Institutes of Health Stroke Scale score (OR, 1.21; 95%CI, 1.10-1.37, p < 0.0001), hematoma volume (OR, 1.41; 95%CI, 1.10-1.90, p = 0.066), and systolic blood pressure (OR, 1.31; 95%CI, 1.00-1.75, p = 0.0422) were independently associated with in-hospital mortality., Conclusions: Although VKA in addition to AP therapy could increase the in-hospital mortality, NOAC and AP did not increase the hematoma volume, stroke severity, or mortality compared to NOAC monotherapy., (Copyright © 2023 Elsevier B.V. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
32. Pregnancy Complications and Impact on Kidney Allograft After Kidney Transplantation in IgA Nephropathy.
- Author
-
Oki R, Unagami K, Kakogawa J, Beppu H, Banno T, Yagisawa T, Kanzawa T, Hirai T, Omoto K, Kitajima K, Shirakawa H, Hoshino J, Takagi T, and Ishida H
- Subjects
- Female, Humans, Allografts, Graft Survival, Kidney physiology, Retrospective Studies, Glomerulonephritis, IGA complications, Glomerulonephritis, IGA surgery, Kidney Failure, Chronic complications, Kidney Transplantation, Pregnancy Complications
- Abstract
Pregnancy in kidney transplantation (KT) recipients has been challenging because of the high risk of maternal, fetal, and renal complications. Although patients with immunoglobulin A nephropathy (IgAN)-chronic kidney disease (CKD) are at a high risk for hypertension in pregnancy (HIP), the maternal risk in KT recipients with IgAN as the etiology remains unclear. We retrospectively reviewed the medical records of pregnant KT recipients who delivered at our hospital. The incidence of maternal and fetal complications and the impact on kidney allografts between the group with IgAN as the primary kidney disease and the group with other primary diseases were compared. The analysis included 73 pregnancies in 64 KT recipients. The IgAN group had a higher incidence of HIP than the non-IgAN group (69% vs. 40%, p = 0.02). IgAN as primary kidney disease and interval from transplantation to conception were associated with HIP (OR 3.33 [1.11-9.92], p = 0.03, OR 0.83 [0.72-0.96], p < 0.01, respectively). The 20-year graft survival or prevention of CKD stage 5 in group with IgAN was lower than that in the group with other primary disease ( p < 0.01). KT recipients should be informed of the risk of HIP and possibility of long-term worsening of postpartum renal function., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Oki, Unagami, Kakogawa, Beppu, Banno, Yagisawa, Kanzawa, Hirai, Omoto, Kitajima, Shirakawa, Hoshino, Takagi and Ishida.)
- Published
- 2023
- Full Text
- View/download PDF
33. Kidney Transplantation After Multiple Urinary Tract Conversion with an Ileal Conduit: A Case Report.
- Author
-
Nagahisa C, Unagami K, Banno T, Oki R, Yagisawa T, Kanzawa T, Hirai T, Omoto K, Ishida H, and Takagi T
- Subjects
- Humans, Female, Middle Aged, Cystectomy methods, Ileum surgery, Kidney Transplantation adverse effects, Urinary Bladder Neoplasms surgery, Urinary Diversion adverse effects, Urinary Diversion methods, Urinary Tract
- Abstract
Background: Kidney transplantation (KTx) after urinary tract conversion surgery is extremely difficult due to several complications. In our case, KTx was performed after multiple operative procedures, including diversion urethrostomy., Case Report: The patient was a 46-year-old woman with a right atrophic kidney, an ectopic opening of the left ureter, and urethral dysplasia since birth. The patient underwent a right nephrectomy, left ureteral sigmoidostomy, Stamey surgery, augmentation ileocystoplasty, and left ureteroileostomy. Thereafter, she underwent nephrostomy, ileal conduit diversion, open sigmoid colectomy, and total cystectomy because of persistent urinary incontinence, sigmoid colon cancer, and recurrent cystitis. Her renal function gradually deteriorated, and hemodialysis was initiated. Before the KTx, she underwent laparoscopic left nephrectomy, an intraperitoneal adhesion debridement, and left ileal conduit resection. We dissected the left ileal conduit in the abdominal cavity and penetrated the anorectal side of the free ileal conduit into the wall of the right side of the abdomen. Thereafter, a kidney from a living donor was transplanted into the right iliac fossa through the existing right ileal conduit when the patient was 46 years old. The allograft function was stable without rejection for 2 years., Conclusions: We report the case of a patient who underwent multiple urethral modifications followed by ileal conduit transfer and living donor KTx, which progressed without major postoperative complications., Competing Interests: Declaration of Competing Interest All the authors declare no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2023 Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
34. The efficacy of neutralizing monoclonal antibodies in transplant recipients with mild-to-moderate COVID-19.
- Author
-
Arimura K, Tagaya E, Kikuchi K, Mitsuda T, Ebihara F, Maruyama T, Hamada Y, Unagami K, Kanzawa T, Sekiguchi H, Shimamoto K, Ishida H, Egawa H, Tanaka J, and Kawana M
- Subjects
- Humans, Transplant Recipients, COVID-19 Drug Treatment, Retrospective Studies, Antibodies, Neutralizing therapeutic use, Oxygen, Antibodies, Monoclonal therapeutic use, COVID-19
- Abstract
Introduction: Transplant recipients (TRs) are at high risk for severe coronavirus disease 2019 (COVID-19). Neutralizing monoclonal antibodies (mAbs) are used for treating mild-to-moderate COVID-19. However, reports comparing the efficacy of COVID-19 treatment without/with mAbs in TRs are limited. We assessed the efficacy of casirivimab/imdevimab against mild-to-moderate COVID-19 in TRs., Methods: Forty-one patients were retrospectively evaluated. The duration until defervescence, oxygen (O
2 ) requirement ≥5 L, and neutralizing antibody levels were compared in TRs with COVID-19 without/with casirivimab/imdevimab., Results: Casirivimab/imdevimab was correlated with shorter duration until defervescence and non-requirement of O2 ≥ 5 L in TRs with COVID-19 [mean: without/with: 6 vs. 2; P = 0.0002, hazard ratio (HR) = 0.3333, 95% confidence interval (CI) = 0.1763-0.6301; 15 vs. 8; P < 0.0001, HR = 0.5333, 95% CI = 0.2878-0.9883; P = 0.0377, HR = 0.1502, 95% CI = 0.02511-0.8980]. Casirivimab/imdevimab was associated with early defervescence after adjusting for sex and age (P = 0.013, HR = 0.412, 95% CI = 0.205-0.826). The antibody levels between patients without/with casirivimab/imdevimab on the day of hospitalization were not significantly different (P = 0.1055), including 13 TRs with vaccination. Antibody levels were higher in patients with casirivimab/imdevimab at 3-5 days after hospitalization than in those without, at 7-9 days after hospitalization (P < 0.0001, mean, without/with: 414.9/40000 AU/mL)., Conclusion: Casirivimab/imdevimab was effective and increased the neutralizing antibody in TRs with mild-to-moderate COVID-19, it may contribute toward preventing the progression., Competing Interests: Declaration of Competing Interest None., (Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.)- Published
- 2023
- Full Text
- View/download PDF
35. Intravenous Alteplase at 0.6 mg/kg for Unknown Onset Stroke with Prior Antithrombotic Medication: THAWS Randomized Clinical Trial.
- Author
-
Koga M, Inoue M, Miwa K, Yoshimura S, Fukuda-Doi M, Aoki J, Asakura K, Kanzawa T, Ohtaki M, Kamiyama K, Yakushiji Y, Igarashi S, Doijiri R, Ito Y, Takagi Y, Sasaki M, Kitazono T, Kimura K, Minematsu K, Yamamoto H, and Toyoda K
- Subjects
- Humans, Diffusion Magnetic Resonance Imaging, Fibrinolytic Agents administration & dosage, Intracranial Hemorrhages, Tissue Plasminogen Activator therapeutic use, Treatment Outcome, Brain Ischemia drug therapy, Stroke drug therapy, Stroke etiology, Stroke prevention & control
- Abstract
Aim: This study aimed to assess the potential effect of prior antithrombotic medication for thrombolysis in an unknown onset stroke., Methods: This was a predefined sub-analysis of the THAWS trial. Stroke patients with a time last known well >4.5 h who had a DWI-fluid-attenuated inversion recovery mismatch were randomly assigned (1:1) to receive alteplase at 0.6 mg/kg (alteplase group) or standard medical treatment (control group). Patients were dichotomized by prior antithrombotic medication., Results: Of 126 patients (intention-to-treat population), 40 took antithrombotic medication (24 with antiplatelets alone, 13 with anticoagulants alone, and 3 with both), and the remaining 86 did not before stroke onset. Of these, 17 and 52 patients, respectively, received alteplase, and 23 and 34, respectively, had standard medical treatment. Antithrombotic therapy was initiated within 24 h after randomization less frequently in the alteplase group (12% vs. 86%, p<0.01). Both any intracranial hemorrhage within 22-36 h (26% vs. 14%) and a modified Rankin Scale score of 0-1 at 90 days (good outcome) (47% vs. 48%) were comparable between the two groups. A good outcome was more common in the alteplase group than in the control group in patients with prior antithrombotic medication [relative risk (RR) 2.25, 95% confidence interval (CI) 1.02-4.99], but it tended to be less common in the alteplase group in those without (RR 0.69, 95% CI 0.46-1.03) (p<0.01 for interaction). The frequency of any intracranial hemorrhage did not significantly differ between the two groups in any patients dichotomized by prior antithrombotic medication., Conclusion: Alteplase appears more beneficial in patients with prior antithrombotic medication.
- Published
- 2023
- Full Text
- View/download PDF
36. A Comparative Study on the Variation in Seropositivity Rates After 2-Dose COVID-19 Vaccination Before or After Transplant: A Single-Center Analysis.
- Author
-
Ishida H, Furusawa M, Unagami K, Kanzawa T, Yagisawa T, Omoto K, Shimizu T, and Takagi T
- Subjects
- Humans, Retrospective Studies, SARS-CoV-2, Treatment Outcome, Vaccination, Transplant Recipients, Antibodies, Viral, Immunosuppressive Agents adverse effects, COVID-19 Vaccines adverse effects, COVID-19 prevention & control
- Abstract
Objectives: Many researchers have demonstrated that the seropositivity rate after SARS-CoV-2 coronavirus vaccination is lower in patients receiving oral immunosuppressants. In this article, we report on a comparative study on the seropositivity rate after 2 doses of coronavirus vaccine before or after kidney transplant., Materials and Methods: We studied 111 recipients vaccinated after transplant, 19 patients vaccinated before transplant, and 10 healthy patients. We retrospectively measured antibody titers using preserved serum samples. The antibody testing was performed 1 month and 3 months after vaccination. The measurement was via LABScreen COVID Plus, which enables simultaneous determination of 5 coronavirus protein antigens., Results: Seropositivity to coronavirus antibodies was observed in all 19 patients vaccinated before transplant (100%) and in all the 10 healthy patients (100%). Forty- six of the 111 recipients (42%) vaccinated after transplant developed seropositivity. Analyzed at each time point after vaccination, the mean fluorescence intensity of antibodies was unchanged between 1 month and 3 months after vaccination in transplant recipients who were vaccinated after transplant and developed seropositivity. On the other hand, the antibody mean fluorescence intensity in patients vaccinated before transplant was markedly lower at 3 months (posttransplant)., Conclusions: All patients with renal failure who were vaccinated before transplant showed a high seropositivity rate, similar to that in healthy patients. The seropositivity rate for each of the viral fragment antibodies in patients vaccinated before transplant was maintained, as seen in healthy patients. However, in patients vaccinated before transplant who tested positive for antibody production at 1 month after vaccination,the antibody mean fluorescence intensity at 3 months after vaccination (posttransplant) was remarkedly lower than the mean fluorescence intensity at 1 month, which was probably caused by the types of immunosuppressive regimens used atthe time of transplant.
- Published
- 2022
- Full Text
- View/download PDF
37. Prior direct oral anticoagulant dosage and outcomes in patients with acute ischemic stroke and non-valvular atrial fibrillation: A sub-analysis of PASTA registry study.
- Author
-
Mashiko T, Fujimoto S, Suda S, Abe A, Iguchi Y, Yagita Y, Kanzawa T, Okubo S, Todo K, Yamazaki M, Nakajima N, Kondo K, Inoue T, Iwanaga T, Terasawa Y, Shibazaki K, and Kimura K
- Subjects
- Administration, Oral, Anticoagulants, Humans, Prospective Studies, Registries, Atrial Fibrillation complications, Atrial Fibrillation drug therapy, Atrial Fibrillation epidemiology, Ischemic Stroke, Kidney Diseases, Stroke complications, Stroke drug therapy
- Abstract
Background and Purpose: Prescribing under-dose direct oral anticoagulants (DOACs) for non-valvular atrial fibrillation (NVAF) is alerted to increase cardiovascular events or death. However, the association between dose selection of DOACs and the clinical course remains unclear. This study aimed to propose a novel criterion for selecting the DOAC dose and investigate clinical characteristics of ischemic stroke (IS) under this criterion., Methods: We assessed the pooled prospective multicenter registry data of stroke patients taking anticoagulant agents, including IS patients with NVAF and prior DOAC usage. The recommended dose according to the reduction criteria of each DOAC and the selected dose were identified for each patient, and patients were categorized into four groups: no alternative low-dose, selecting low-dose appropriately with all DOACs applicable for reduction criteria; selected low-dose, selecting low-dose appropriately or inappropriately despite at least one DOAC inapplicable for reduction criteria; selected standard-dose, appropriate standard-dose use; and absolute over-dose, inappropriate standard-dose regardless of criteria. We investigated the effects of dose selection of DOACs on short-term poor functional outcomes., Results: 322 patients were included in the analysis. The prevalence of no alternative low-dose, selected low-dose, selected standard-dose, and absolute over-dose was 74 (23%), 144 (45%), 89 (27%), and 15 (5%), respectively. Multivariable analysis found that the selected low-dose group showed significantly poorer functional outcomes than the selected standard-dose group only in patients without renal dysfunction (OR, 2.60; 95% CI, 1.17-6.00; P = 0.0186)., Conclusions: Selecting a low dose DOAC might be associated with poor functional outcomes in patients without renal dysfunction., (Copyright © 2022 Elsevier B.V. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
38. Characteristics of Ischemic Versus Hemorrhagic Stroke in Patients Receiving Oral Anticoagulants: Results of the PASTA Study.
- Author
-
Suda S, Abe A, Iguchi Y, Yagita Y, Kanzawa T, Okubo S, Ohara N, Mizunari T, Yamazaki M, Nakajima N, Kondo K, Fujimoto S, Inoue T, Iwanaga T, Terasawa Y, Shibazaki K, Kono Y, Nakajima M, Nakajima M, Mishina M, Adachi K, Imafuku I, Nomura K, Nagao T, Yaguchi H, Okamoto S, Osaki M, and Kimura K
- Subjects
- Administration, Oral, Anticoagulants adverse effects, Humans, Vitamin K therapeutic use, Atrial Fibrillation complications, Atrial Fibrillation drug therapy, Hemorrhagic Stroke, Stroke epidemiology, Stroke etiology
- Abstract
Objective Limited data exist regarding the comparative detailed clinical characteristics of patients with ischemic stroke (IS)/transient ischemic attack (TIA) and intracerebral hemorrhage (ICH) receiving oral anticoagulants (OACs). Methods The prospective analysis of stroke patients taking oral anticoagulants (PASTA) registry, a multicenter registry of 1,043 stroke patients receiving OACs [vitamin K antagonists (VKAs) or non-vitamin K antagonist oral anticoagulant (NOACs)] across 25 medical institutions throughout Japan, was used. Univariate and multivariable analyses were used to analyze differences in clinical characteristics between IS/TIA and ICH patients with atrial fibrillation (AF) who were registered in the PASTA registry. Results There was no significant differences in cardiovascular risk factors, such as hypertension, diabetes mellitus, dyslipidemia, smoking, or alcohol consumption (all p>0.05), between IS/TIA and ICH among both NOAC and VKA users. Cerebral microbleeds (CMBs) [odds ratio (OR), 4.77; p<0.0001] were independently associated with ICH, and high brain natriuretic peptide/N-terminal pro B-type natriuretic peptide levels (OR, 1.89; p=0.0390) were independently associated with IS/TIA among NOAC users. A history of ICH (OR, 13.59; p=0.0279) and the high prothrombin time-international normalized ratio (PT-INR) (OR, 1.17; p<0.0001) were independently associated with ICH, and a history of IS/TIA (OR, 3.37; 95% CI, 1.34-8.49; p=0.0101) and high D-dimer levels (OR, 2.47; 95% CI, 1.05-5.82; p=0.0377) were independently associated with IS/TIA among VKA users. Conclusion The presence of CMBs, a history of stroke, natriuretic peptide and D-dimer levels, and PT-INR may be useful for risk stratification of either IS/TIA or ICH development in patients with AF receiving OACs.
- Published
- 2022
- Full Text
- View/download PDF
39. Sustained atrial fibrillation is related to a higher severity of stroke in patients taking direct oral anticoagulants.
- Author
-
Hayashi T, Suda S, Abe A, Iguchi Y, Yagita Y, Kanzawa T, Okubo S, Fujimoto S, and Kimura K
- Subjects
- Administration, Oral, Aged, Aged, 80 and over, Anticoagulants adverse effects, Hospitalization, Humans, Male, Risk Factors, Atrial Fibrillation complications, Atrial Fibrillation drug therapy, Stroke complications
- Abstract
Background: Atrial fibrillation (AF) includes paroxysmal and sustained (persistent or permanent) AF, and both forms are considered risk factors for ischemic stroke. This study aimed to investigate the differences in stroke severity at admission between patients with paroxysmal AF and sustained AF when treated with direct oral anticoagulants (DOACs)., Methods: Using data from DOAC-treated 300 nonvalvular patients with AF and acute anterior circulation stroke who were registered in the Multicenter Prospective Analysis of Stroke Patients Taking Oral Anticoagulants study, patients were divided into two groups, namely, paroxysmal AF and sustained AF. We compared the clinical characteristics between the two groups and determined the effect of these two types of AF on stroke severity on admission., Results: Of 300 patients, 246 (males, n = 149; median age, 80 years) and 54 (males, n = 32; median age, 78 years) were assigned to the sustained AF and paroxysmal AF groups, respectively. The sustained AF group had a higher proportion of severe stroke (National Institutes of Health Stroke Scale score, >20) on admission (22.0% vs. 5.7%, p = 0.006) and internal carotid artery occlusion (11.4% vs. 1.9%, p = 0.03) compared to the paroxysmal AF group. Multivariate analysis showed that sustained AF was independently associated with severe stroke on admission (odds ratio 4.31, 95% confidence interval 1.24-15.0, p = 0.02)., Conclusions: Sustained AF was associated with a higher severity of stroke accompanied with major vessel occlusion than paroxysmal AF, even prior to DOACs treatment. Registration https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000034958., (Copyright © 2022 Elsevier B.V. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
40. Safe Renal Transplantation to the Extraperitoneal Cavity in Children Weighing Less Than 15 kg.
- Author
-
Hata K, Ishida H, Ishizuka K, Unagami K, Kanzawa T, Omoto K, Shimizu T, Miura K, Hattori M, and Tanabe K
- Subjects
- Adolescent, Adult, Child, Humans, Kidney surgery, Postoperative Complications etiology, Retrospective Studies, Transplantation, Homologous, Kidney Failure, Chronic etiology, Kidney Failure, Chronic surgery, Kidney Transplantation adverse effects, Kidney Transplantation methods
- Abstract
Pediatric renal transplantation is associated with various surgical complications due to the complexity of the technique and the often-fragile condition of patients with end-stage renal disease. We evaluated the surgical complications associated with renal transplantation via the extraperitoneal approach in pediatric recipients. This retrospective study enrolled 280 patients younger than 16 years old who underwent renal transplantation via the extraperitoneal approach: 216 patients underwent transplant placement in the iliac fossa like in adults, and 64 underwent transplant placement in the distal part of the original renal lower pole (the extraperitoneal cavity). On the basis of the Clavien-Dindo classification, 30 patients (10.7%) showed grade 2 complications and 12 patients (4.3%) showed grade 3 or higher complications. None of the patients showed gastrointestinal complications. In a Cox regression analysis, grade 2 or higher complications were significantly associated with weight less than 15 kg (P = .027) and operative times longer than 245 minutes (P = .029). Among the 49 patients weighing less than 15 kg with an allograft placed in a distal portion of the original renal lower pole, only 3 patients (6.1%) developed surgical complications. Thus, allograft placement in the extraperitoneal cavity can be performed safely in children weighing less than 15 kg., (Copyright © 2022 Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
41. Role of Fractalkine-CX3CR1 Axis in Acute Rejection of Mouse Heart Allografts Subjected to Ischemia Reperfusion Injury.
- Author
-
Kanzawa T, Tokita D, Saiga K, Yamakawa T, Ishigooka H, Fukuda H, Katsumata H, Miyairi S, Ishii R, Hirai T, Imai T, Okumi M, and Tanabe K
- Subjects
- Adoptive Transfer, Allografts, Animals, Graft Survival, Mice, Mice, Inbred BALB C, Mice, Inbred C57BL, Monocytes, CX3C Chemokine Receptor 1 metabolism, Chemokine CX3CL1 metabolism, Graft Rejection, Heart Transplantation, Reperfusion Injury
- Abstract
Transplantation outcomes are affected by the increase in rejection associated with ischemia reperfusion injury (IRI). Fractalkine (FKN), a chemokine for recruitment of CX3CR1
+ leukocytes, contributes to the pathogenesis of various inflammatory diseases. Herein, we evaluated the importance of the FKN-CX3CR1 axis during IRI-related rejections using a mouse heterotopic heart transplantation model. FKN expression and graft survival was compared between wild-type C57BL/6 recipients transplanted with BALB/c hearts preserved for 8 (WT-IRI) and 0.5 h (WT-control) at 4°C. Graft survival of WT-IRI was shorter than that of WT-control. FKN was expressed on the vascular endothelium in WT-IRI allografts, but minimally in WT-control. The role of the FKN-CX3CR1 axis in IRI-related rejection was directly investigated using the transplant model with CX3CR1-deficient recipients (CX3CR1 KO-IRI) or treatment with anti-mouse FKN monoclonal antibodies. Graft survival of CX3CR1 KO-IRI was longer than that of WT-IRI; antibody treatment prolonged graft survival. The contribution of CX3CR1+ monocytes to IRI-related rejection was evaluated by adoptive transfer to CX3CR1 KO-IRI. Adoptive transfer of CX3CR1+ monocytes attenuated the effect of prolonged graft survival in CX3CR1 KO-IRI. Overall, the FKN-CX3CR1 axis plays a major role during IRI-related rejection; its blockade has the potential to improve the outcomes of deceased donor transplantation., Competing Interests: Author TI is employed by the company KAN Research Institute, Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Kanzawa, Tokita, Saiga, Yamakawa, Ishigooka, Fukuda, Katsumata, Miyairi, Ishii, Hirai, Imai, Okumi and Tanabe.)- Published
- 2022
- Full Text
- View/download PDF
42. Desensitization Regimen Consisting of High-Dose Intravenous Immunoglobulin, Plasmapheresis, and Rituximab (an Anti-CD20 Antibody), Without Eculizumab and/or Bortezomib, in 41 Highly Sensitized Kidney Transplant Recipients.
- Author
-
Ishida H, Unagami K, Omoto K, Kanzawa T, and Tanabe K
- Subjects
- Antibodies, Monoclonal, Humanized, Bortezomib adverse effects, Desensitization, Immunologic adverse effects, Desensitization, Immunologic methods, Female, Graft Rejection, Graft Survival, HLA Antigens, Histocompatibility Testing, Humans, Immunoglobulins, Intravenous adverse effects, Male, Oliguria drug therapy, Plasmapheresis adverse effects, Retrospective Studies, Rituximab adverse effects, Transplant Recipients, Treatment Outcome, Anuria, Kidney Transplantation adverse effects, Kidney Transplantation methods
- Abstract
Objectives: Antibody-mediated rejection in patients with positive crossmatches can be severe and result in sudden onset of oliguria, leading to graft loss. In an attempt to prevent posttransplant oliguria, we adopted a preoperative desensitization protocol involving the use of high-dose intravenous immunoglobulin/plasmapheresis and the anti-CD20 antibody, rituximab, in 41 transplant recipients with positive crossmatch test results., Materials and Methods: We retrospectively examined the clinical courses of the 41 kidney transplant recipients, paying special attention to renal graft function, urine volume, and changes in the titers of donor-specific antibodies., Results: Four grafts were lost during an average of 4.5-year follow-up. Average graft function was excellent, with a serum creatinine level of 1.3 ± 0.4 mg/dL. Sufficient urine output, with no oliguria or anuria, was achieved postoperatively in 40 of the 41 patients. However, among the 34 patients who underwent graft biopsies, the biopsies revealed acute antibody-mediated rejection in 21 patients (62%), and chronic antibodymediated rejection in 10 patients (30%)., Conclusions: The high-dose intravenous immunoglobulin treatment included in our desensitization protocol was shown to be safe and effective for achieving successful transplant outcomes and allowed the avoidance of more aggressive B-cell-targeted treatments, such as C5 inhibitors and/or proteosome inhibitors, for preventing posttransplant oliguria and anuria.
- Published
- 2021
- Full Text
- View/download PDF
43. Robot-Assisted Laparoscopic Partial Nephrectomy for Allograft Renal Cell Carcinoma: A Case Report.
- Author
-
Watanabe S, Takagi T, Yoshida K, Unagami K, Kanzawa T, Iizuka J, Ishida H, and Tanabe K
- Subjects
- Aged, Carcinoma, Renal Cell pathology, Humans, Kidney pathology, Kidney Neoplasms pathology, Kidney Transplantation, Laparoscopy, Male, Middle Aged, Robotic Surgical Procedures, Tomography, X-Ray Computed, Transplantation, Homologous, Carcinoma, Renal Cell surgery, Kidney Neoplasms surgery, Nephrectomy methods
- Abstract
Background: Nephron-sparing surgery is required for patients with kidney transplant with organ-confined renal cell carcinoma (RCC) in the allograft kidney to preserve renal function. Robot-assisted laparoscopic partial nephrectomy (RAPN) is expected to be the optimal surgical approach for these patients, as in the general population. However, RAPN for RCC arising in the allograft kidney is rarely reported. Here, we report 2 cases of patients who underwent RAPN for allograft RCC., Case Presentation: Two patients were diagnosed with RCC in the renal allograft based on enhanced computed tomography findings. Case 1 was a 69-year-old man with a 32-mm mass in the middle portion of the right iliac fossa renal allograft, and case 2 was a 55-year-old man with a 24-mm mass in the lower pole of the right iliac fossa renal allograft. In each patient, RAPN was performed for the renal mass through a transperitoneal approach, with clamping of the renal artery. No major perioperative complications occurred in either patient, negative surgical margins were achieved, and no significant changes in kidney function were observed during either surgery. Pathologic findings showed clear cell RCC in case 1 and papillary RCC in case 2., Conclusion: RAPN can be a feasible and effective treatment option for allograft RCC., (Copyright © 2021 Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
44. Magnetic Resonance Imaging-Guided Thrombolysis (0.6 mg/kg) Was Beneficial for Unknown Onset Stroke Above a Certain Core Size: THAWS RCT Substudy.
- Author
-
Toyoda K, Inoue M, Yoshimura S, Yamagami H, Sasaki M, Fukuda-Doi M, Kimura K, Asakura K, Miwa K, Kanzawa T, Ihara M, Kondo R, Shiozawa M, Ohtaki M, Kamiyama K, Itabashi R, Iwama T, Aoki J, Minematsu K, Yamamoto H, and Koga M
- Subjects
- Aged, Aged, 80 and over, Diffusion Magnetic Resonance Imaging methods, Female, Humans, Male, Stroke pathology, Time Factors, Fibrinolytic Agents therapeutic use, Stroke diagnostic imaging, Stroke drug therapy, Thrombolytic Therapy methods, Tissue Plasminogen Activator therapeutic use
- Abstract
Background and Purpose: We determined to identify patients with unknown onset stroke who could have favorable 90-day outcomes after low-dose thrombolysis from the THAWS (Thrombolysis for Acute Wake-Up and Unclear-Onset Strokes With Alteplase at 0.6 mg/kg) database., Methods: This was a subanalysis of an investigator-initiated, multicenter, randomized, open-label, blinded-end point trial. Patients with stroke with a time last-known-well >4.5 hours who showed a mismatch between diffusion-weighted imaging (DWI) and fluid-attenuated inversion recovery were randomly assigned (1:1) to receive alteplase at 0.6 mg/kg intravenously or standard medical treatment. The patients were dichotomized by ischemic core size or National Institutes of Health Stroke Scale score, and the effects of assigned treatments were compared in each group. The efficacy outcome was favorable outcome at 90 days, defined as a modified Rankin Scale score of 0 to 1., Results: The median DWI-Alberta Stroke Program Early CT Score (ASPECTS) was 9, and the median ischemic core volume was 2.5 mL. Both favorable outcome (47.1% versus 48.3%) and any intracranial hemorrhage (26% versus 14%) at 22 to 36 hours were comparable between the 68 thrombolyzed patients and the 58 control patients. There was a significant treatment-by-cohort interaction for favorable outcome between dichotomized patients by ASPECTS on DWI ( P =0.026) and core volume ( P =0.035). Favorable outcome was more common in the alteplase group than in the control group in patients with DWI-ASPECTS 5 to 8 (RR, 4.75 [95% CI, 1.33-30.2]), although not in patients with DWI-ASPECTS 9 to 10. Favorable outcome tended to be more common in the alteplase group than in the control group in patients with core volume >6.4 mL (RR, 6.15 [95% CI, 0.87-43.64]), although not in patients with volume ≤6.4 mL. The frequency of any intracranial hemorrhage did not differ significantly between the 2 treatment groups in any dichotomized patients., Conclusions: Patients developing unknown onset stroke with DWI-ASPECTS 5 to 8 showed favorable outcomes more commonly after low-dose thrombolysis than after standard treatment. Registration: URL: https://www.clinicaltrials.gov; Unique Identifier: NCT02002325. URL: https://www.umin.ac.jp/ctr; Unique Identifier: UMIN000011630.
- Published
- 2021
- Full Text
- View/download PDF
45. Predicting the outcome of non-pharmacological treatment for patients with dementia-related mild cognitive impairment.
- Author
-
Shigihara Y, Hoshi H, Poza J, Rodríguez-González V, Gómez C, and Kanzawa T
- Subjects
- Aged, Aged, 80 and over, Clinical Decision-Making, Cognitive Dysfunction diagnosis, Cognitive Dysfunction physiopathology, Cognitive Dysfunction psychology, Dementia diagnosis, Dementia physiopathology, Dementia psychology, Female, Humans, Male, Mental Status and Dementia Tests, Middle Aged, Predictive Value of Tests, Treatment Outcome, Brain physiopathology, Brain Mapping, Brain Waves, Cognition, Cognitive Dysfunction therapy, Dementia therapy, Magnetoencephalography
- Abstract
Dementia is a progressive cognitive syndrome, with few effective pharmacological treatments that can slow its progress. Hence, non-pharmacological treatments (NPTs) play an important role in improving patient symptoms and quality of life. Designing the optimal personalised NPT strategy relies on objectively and quantitatively predicting the treatment outcome. Magnetoencephalography (MEG) findings can reflect the cognitive status of patients with dementia, and thus potentially predict NPT outcome. In the present study, 16 participants with cognitive impairment underwent NPT for several months. Their cognitive performance was evaluated based on the Mini-Mental State Examination and the Alzheimer's Disease Assessment Scale - Cognitive at the beginning and end of the NPT period, while resting-state brain activity was evaluated using MEG during the NPT period. Our results showed that the spectral properties of MEG signals predicted the changes in cognitive performance scores. High frequency oscillatory intensity at the right superior frontal gyrus medial segment, opercular part of the inferior frontal gyrus, triangular part of the inferior frontal gyrus, post central gyrus, and angular gyrus predicted the changes in cognitive performance scores. Thus, resting-state brain activity may be a powerful tool in designing personalised NPT.
- Published
- 2020
- Full Text
- View/download PDF
46. Risk factors, etiology, and outcome of ischemic stroke in young adults: A Japanese multicenter prospective study.
- Author
-
Kono Y, Terasawa Y, Sakai K, Iguchi Y, Nishiyama Y, Nito C, Suda S, Kimura K, Kanzawa T, Imafuku I, Nakayama T, Ueda M, Iwanaga T, Kono T, Yamashiro K, Tanaka R, Okubo S, Nakajima M, Nakajima N, Mishina M, Yaguchi H, Oka H, Suzuki M, Osaki M, Kaneko N, Kitagawa K, Okamoto S, Nomura K, Yamazaki M, Nagao T, and Murakami Y
- Subjects
- Adolescent, Adult, Female, Humans, Japan epidemiology, Male, Middle Aged, Prospective Studies, Risk Factors, Young Adult, Brain Ischemia epidemiology, Ischemic Stroke, Stroke epidemiology, Stroke etiology
- Abstract
Purpose: This study aimed to evaluate the risk factors, etiology, and outcomes of ischemic stroke (IS) in Japanese young adults., Methods: This was a prospective multicenter study. We enrolled patients aged 16 to 55 years with IS within seven days of the onset of symptoms. We assessed the demographic data, risk factors, stroke etiology, and outcome at discharge. The clinical characteristics were compared between sexes and among age groups., Results: We prospectively enrolled 519 patients (median age, 48 years: 139 females). The mean National Institute of Health Stroke Scale score was 3.6 ± 0.2. The most common risk factors were hypertension (HT) (55%), dyslipidemia (DL) (47%), and current smoking (42%). Body mass index, incidence of current smoking, and heavy alcohol consumption were higher in males. The prevalence of current smoking, HT, DL, and diabetes mellitus increased with aging. The most common etiologic subgroup of IS was small vessel disease (145/510, 28%). Intracranial arterial dissection (IAD) was the most common among the other determined causes (56/115, 49%). The outcome at discharge was relatively good (mRS 0-1, 71.7%); however, poor outcome (mRS ≥ 4) was observed at an incidence of 9.5%., Conclusions: Most young adults with IS had modifiable risk factors, of which prevalence increased with age. This emphasizes lifestyle improvement to prevent IS in the young population. Furthermore, we indicated that the incidence rate of IAD was high among the other determined causes., (Copyright © 2020. Published by Elsevier B.V.)
- Published
- 2020
- Full Text
- View/download PDF
47. Impact of donor-related arteriosclerosis in pretransplant biopsy on long-term outcome of living-kidney transplantation: A propensity score-matched cohort study.
- Author
-
Kakuta Y, Okumi M, Kanzawa T, Unagami K, Iizuka J, Takagi T, Ishida H, and Tanabe K
- Subjects
- Adult, Biopsy, Cohort Studies, Graft Rejection epidemiology, Graft Rejection etiology, Graft Survival, Humans, Living Donors, Propensity Score, Arteriosclerosis epidemiology, Kidney Transplantation adverse effects
- Abstract
Objectives: To compare the long-term outcome and complications of living-kidney grafts with arteriosclerosis to those without abnormal findings diagnosed using pretransplant graft biopsy, and to assess the impact of the arteriosclerosis in living-donor kidneys., Methods: The influence of arteriosclerosis in pretransplant biopsy on long-term outcomes and complications was evaluated in both unmatched (n = 1351, without arteriosclerosis n = 788 vs with arteriosclerosis n = 563) and propensity score-matched cohorts (n = 984, without arteriosclerosis n = 492 vs with arteriosclerosis n = 492) of adults who underwent living-kidney transplant., Results: In both the unmatched and matched cohort, there was no significant difference in patient and death-censored graft survival at 10 years between the without arteriosclerosis and with arteriosclerosis groups. The with arteriosclerosis group had a higher incidence rate of overall rejection than did the without arteriosclerosis group in both the unmatched (P = 0.026) and matched (P = 0.060) cohorts. The with arteriosclerosis group had significantly higher chronic antibody-mediated rejection than did the without arteriosclerosis group (P = 0.006) in the unmatched cohort. The with arteriosclerosis group had a significantly lower estimated glomerular filtration rate in recipients, but there was no significant difference after matching. The incidence rates of calcineurin inhibitor nephrotoxicity and post-transplant anemia were significantly higher in the with arteriosclerosis group than in the without arteriosclerosis group in both the unmatched and matched cohorts. Long-term postoperative kidney function of living donors was lower in the with arteriosclerosis group., Conclusions: Kidney graft with arteriosclerosis might affect the incidence of rejection, complications and postoperative kidney function of donors. Long-term careful observation is required for both the recipients who received grafts with arteriosclerosis and the donors who had kidneys with arteriosclerosis., (© 2020 The Japanese Urological Association.)
- Published
- 2020
- Full Text
- View/download PDF
48. Thrombolysis With Alteplase at 0.6 mg/kg for Stroke With Unknown Time of Onset: A Randomized Controlled Trial.
- Author
-
Koga M, Yamamoto H, Inoue M, Asakura K, Aoki J, Hamasaki T, Kanzawa T, Kondo R, Ohtaki M, Itabashi R, Kamiyama K, Iwama T, Nakase T, Yakushiji Y, Igarashi S, Nagakane Y, Takizawa S, Okada Y, Doijiri R, Tsujino A, Ito Y, Ohnishi H, Inoue T, Takagi Y, Hasegawa Y, Shiokawa Y, Sakai N, Osaki M, Uesaka Y, Yoshimura S, Urabe T, Ueda T, Ihara M, Kitazono T, Sasaki M, Oita A, Yoshimura S, Fukuda-Doi M, Miwa K, Kimura K, Minematsu K, and Toyoda K
- Subjects
- Aged, Aged, 80 and over, Diffusion Magnetic Resonance Imaging, Dose-Response Relationship, Drug, Female, Humans, Intracranial Hemorrhages chemically induced, Male, Middle Aged, Stroke diagnostic imaging, Treatment Outcome, Fibrinolytic Agents administration & dosage, Stroke drug therapy, Thrombolytic Therapy methods, Time-to-Treatment, Tissue Plasminogen Activator administration & dosage
- Abstract
Background and Purpose- We assessed whether lower-dose alteplase at 0.6 mg/kg is efficacious and safe for acute fluid-attenuated inversion recovery-negative stroke with unknown time of onset. Methods- This was an investigator-initiated, multicenter, randomized, open-label, blinded-end point trial. Patients met the standard indication criteria for intravenous thrombolysis other than a time last-known-well >4.5 hours (eg, wake-up stroke). Patients were randomly assigned (1:1) to receive alteplase at 0.6 mg/kg or standard medical treatment if magnetic resonance imaging showed acute ischemic lesion on diffusion-weighted imaging and no marked corresponding hyperintensity on fluid-attenuated inversion recovery. The primary outcome was a favorable outcome (90-day modified Rankin Scale score of 0-1). Results- Following the early stop and positive results of the WAKE-UP trial (Efficacy and Safety of MRI-Based Thrombolysis in Wake-Up Stroke), this trial was prematurely terminated with 131 of the anticipated 300 patients (55 women; mean age, 74.4±12.2 years). Favorable outcome was comparable between the alteplase group (32/68, 47.1%) and the control group (28/58, 48.3%; relative risk [RR], 0.97 [95% CI, 0.68-1.41]; P =0.892). Symptomatic intracranial hemorrhage within 22 to 36 hours occurred in 1/71 and 0/60 (RR, infinity [95% CI, 0.06 to infinity]; P >0.999), respectively. Death at 90 days occurred in 2/71 and 2/60 (RR, 0.85 [95% CI, 0.06-12.58]; P >0.999), respectively. Conclusions- No difference in favorable outcome was seen between alteplase and control groups among patients with ischemic stroke with unknown time of onset. The safety of alteplase at 0.6 mg/kg was comparable to that of standard treatment. Early study termination precludes any definitive conclusions. Registration- URL: https://www.clinicaltrials.gov; Unique identifier: NCT02002325.
- Published
- 2020
- Full Text
- View/download PDF
49. Multicenter Prospective Analysis of Stroke Patients Taking Oral Anticoagulants: The PASTA Registry - Study Design and Characteristics.
- Author
-
Suda S, Iguchi Y, Fujimoto S, Yagita Y, Kono Y, Ueda M, Todo K, Kono T, Mizunari T, Yamazaki M, Kanzawa T, Okubo S, Kondo K, Nakajima N, Inoue T, Iwanaga T, Nakajima M, Imafuku I, Shibazaki K, Mishina M, Adachi K, Nomura K, Nakajima M, Yaguchi H, Okamoto S, Osaki M, Terasawa Y, Nagao T, and Kimura K
- Subjects
- Administration, Oral, Aged, Anticoagulants adverse effects, Atrial Fibrillation diagnosis, Atrial Fibrillation epidemiology, Brain Ischemia diagnosis, Brain Ischemia epidemiology, Cerebral Hemorrhage diagnosis, Cerebral Hemorrhage epidemiology, Female, Guideline Adherence, Humans, Inappropriate Prescribing, Japan epidemiology, Male, Practice Guidelines as Topic, Practice Patterns, Physicians', Prospective Studies, Registries, Risk Assessment, Risk Factors, Stroke diagnosis, Stroke epidemiology, Time Factors, Treatment Outcome, Venous Thrombosis diagnosis, Venous Thrombosis epidemiology, Anticoagulants administration & dosage, Atrial Fibrillation drug therapy, Brain Ischemia therapy, Cerebral Hemorrhage therapy, Research Design, Stroke therapy, Venous Thrombosis drug therapy
- Abstract
Objectives: The management of atrial fibrillation and deep venous thrombosis has evolved with the development of direct oral anticoagulants (DOAC), and oral anticoagulant (OAC) might influence the development or clinical course in both ischemic and hemorrhagic stroke. However, detailed data on the differences between the effects of the prior prescription of warfarin and DOAC on the clinical characteristics, neuroradiologic findings, and outcome of stroke are limited., Design: The prospective analysis of stroke patients taking anticoagulants (PASTA) registry study is an observational, multicenter, prospective registry of stroke (ischemic stroke, transient ischemic attack, and intracerebral hemorrhage) patients receiving OAC in Japan. This study is designed to collect data on clinical background characteristics, drug adherence, drug dosage, neurological severity at admission and discharge, infarct or hematoma size, acute therapy including recanalization therapy or reverse drug therapy, and timing of OAC re-initiation. Patient enrollment started in April 2016 and the target patient number is 1000 patients., Conclusions: The PASTA prospective registry should identify the status of stroke patients taking OAC in the current clinical practice in Japan., (Copyright © 2019 Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
50. Effect of Standard vs Intensive Blood Pressure Control on the Risk of Recurrent Stroke: A Randomized Clinical Trial and Meta-analysis.
- Author
-
Kitagawa K, Yamamoto Y, Arima H, Maeda T, Sunami N, Kanzawa T, Eguchi K, Kamiyama K, Minematsu K, Ueda S, Rakugi H, Ohya Y, Kohro T, Yonemoto K, Okada Y, Higaki J, Tanahashi N, Kimura G, Umemura S, Matsumoto M, Shimamoto K, Ito S, Saruta T, and Shimada K
- Abstract
Importance: The Systolic Blood Pressure Intervention Trial (SPRINT) demonstrated that a systolic blood pressure (BP) target less than 120 mm Hg was superior to less than 140 mm Hg for preventing vascular events. This trial excluded patients with prior stroke; therefore, the ideal BP target for secondary stroke prevention remains unknown., Objective: To assess whether intensive BP control would achieve fewer recurrent strokes vs standard BP control., Design, Setting, and Participants: Randomized clinical trial (RCT) of standard vs intensive BP control in an intent-to-treat population of patients who had a history of stroke. Patients were enrolled between October 20, 2010, and December 7, 2016. For an updated meta-analysis, PubMed and the Cochrane Central Library database were searched through September 30, 2018, using the Medical Subject Headings and relevant search terms for cerebrovascular disease and for intensive BP lowering. This was a multicenter trial that included 140 hospitals in Japan; 1514 patients who had a history of stroke within the previous 3 years were approached, but 234 refused to give informed consent., Interventions: In total, 1280 patients were randomized 1:1 to BP control to less than 140/90 mm Hg (standard treatment) (n = 640) or to less than 120/80 mm Hg (intensive treatment) (n = 640). However, 17 patients never received intervention; therefore, 1263 patients assigned to standard treatment (n = 630) or intensive treatment (n = 633) were analyzed., Main Outcomes and Measures: The primary outcome was stroke recurrence., Results: The trial was stopped early. Among 1263 analyzed patients (mean [SD] age, 67.2 [8.8] years; 69.4% male), 1257 of 1263 (99.5%) completed a mean (SD) of 3.9 (1.5) years of follow-up. The mean BP at baseline was 145.4/83.6 mm Hg. Throughout the overall follow-up period, the mean BP was 133.2/77.7 (95% CI, 132.5-133.8/77.1-78.4) mm Hg in the standard group and 126.7/77.4 (95% CI, 125.9-127.2/73.8-75.0) mm Hg in the intensive group. Ninety-one first recurrent strokes occurred. Nonsignificant rate reductions were seen for recurrent stroke in the intensive group compared with the standard group (hazard ratio [HR], 0.73; 95% CI, 0.49-1.11; P = .15). When this finding was pooled in 3 previous relevant RCTs in a meta-analysis, the risk ratio favored intensive BP control (relative risk, 0.78; 95% CI, 0.64-0.96; P = .02; absolute risk difference, -1.5%; 95% CI, -2.6% to -0.4%; number needed to treat, 67; 95% CI, 39-250)., Conclusions and Relevance: Intensive BP lowering tended to reduce stroke recurrence. The updated meta-analysis supports a target BP less than 130/80 mm Hg in secondary stroke prevention., Trial Registration: ClinicalTrials.gov identifier: NCT01198496.
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.